Method of predicting development of arterial hypertension in pregnant women

FIELD: medicine.

SUBSTANCE: method of predicting development of arterial hypertension in pregnant women consists of realisation of DNA separation from peripheral venous blood, carrying out polymerase chain reaction, finding out data about presence of polymorphism of α-adducin 1 gene. If carrying genotype 460WW of gene of α-adducin 1 ADD1 G460W is detected, conclusion about risk of hypertension development in pregnant women is made.

EFFECT: increased efficiency of predicting arterial hypertension development in pregnant women.

1 ex, 1 tbl, 2 dwg

 

The invention relates to the field of medical diagnostics, can be used to predict the development of hypertension in pregnant women.

Arterial hypertension (AH) is a disease that is characterized by a persistent increase in blood pressure. Changes occurring in the body during pregnancy, predispose to the development of hypertension and pregnant because the risk of developing hypertension is higher than among the General population [1]. Hypertension in pregnancy occurs in 5-15% of women and significantly complicates its forecast; it is a leading cause of maternal mortality, preterm birth, perinatal loss, and cardiovascular diseases [2]. AG is of great danger not only for the mother but also for the fetus. Under the action of high blood pressure changes, the structure of the blood vessels of the woman's body, which in turn leads to disruption of blood supply to tissues and organs [3]. The syndrome of pre-eclampsia/eclampsia, the main element of which is hypertension of pregnancy as a time characterized by impaired blood circulation and kidney damage. It should be noted that eclampsia refers to extremely dangerous conditions of pregnancy [1]. To date, accumulated a wealth of information indicating that in R the development of hypertension genetic factors can play a significant role [4]. This pathology is polygenic in nature. According to experimental and clinical data, important role in the development of pathology play a so-called genes - candidates "vascular reactions", involved in the regulation of blood pressure[5, 6, 7, 8, 9].

Authors available in the medical-scientific and patent literature is not detected estimation method for predicting the development of hypertension in pregnant women based on the genetic polymorphism of α-adducin 1.

The goal of this research is to develop a method for evaluating forecasting the development of hypertension in pregnant women based on the polymorphism of the gene of α-adducin 1.

The main task of the molecular-genetic typing locus of the gene of α-adducin 1 - the definition of single nucleotide polymorphisms in the gene that causes the replacement of the amino acid glycine at trypophan 460-m codon of the polypeptide molecules that can influence the development of hypertensive reactions during pregnancy.

The technical result of the invention is to obtain criteria for the development of hypertension in pregnant women, allowing in a short period of time to determine the clinical prognosis and strategy for therapy of this disease.

In accordance with the task, developed a method of assessing the state of the cardiovascular system in the ber is built on the basis of the analysis of gene polymorphism of α-adducin 1, consisting of DNA isolation from peripheral venous blood and carrying out polymerase chain reaction. Conclusion on the risk of development of hypertension in pregnant women do in case of carriage of genotype 460WW gene α-adducin 1 ADD1 G460W.

Novelty and inventive step lies in the fact that the prior art is no way to determine the risk of developing high blood pressure in pregnant women for the presence of alleles and genotypes of the gene of α-adducin 1.

The method is as follows.

DNA extracted from peripheral venous blood samples of pregnant women in 2 stages. At the first stage to 4 ml of blood add 25 ml of lyse buffer containing 320 mm sucrose, 1% Triton X-100, 5 mm MgCl2, 10 mm Tris-HCl (pH=7,6). The resulting mixture was stirred and centrifuged at 4°C, 4000 rpm for 20 minutes. After centrifugation the supernatant is poured, to the precipitate add 4 ml of a solution containing 25 mm EDTA (pH 8,0) and 75 mm NaCl, resuspension. Then add 0.4 ml of 10% SDS, 35 ál of proteinase K (10 mg/ml) and incubated at 37°C for 16 hours.

In the second stage of the lysate obtained consistently carried out the DNA extraction with equal volumes of phenol, phenol-chloroform (1:1) and chloroform by centrifugation at 4000 rpm for 10 minutes. After each centrifugation produce the selection of the aqueous phase. DNA is precipitated from the solution with two volumes of the cooled 96% ethanol. Formed DNA is dissolved in twice distilled, deionized water and stored at -20°C.

The selected DNA is then subjected to polymerase chain reaction in real time (real-time PCR) using standard oligonucleotide primers and oligonucleotide probes type TaqMan.

Polymerase chain reaction (PCR) synthesis of polymorphic loci α-adducin 1 is performed in 25 μl total volume of a mixture containing 65 mm Tris-HCl (pH 8,8), 2.5 mm MgCl2, 1 µg of genomic DNA, 10 PM of each primer and probe, 100 μm dATP, dGTP, dCTP, dTTP and 2 active units Taq polymerase. Temperature regimes PCR and sequencing primers and probes are listed in the table.

The sequence of primers and probes, temperature Protocol, the length of the amplified fragment locus ADD1 G460W
The sequence of primers and probesThe length of the amplified fragmentTemperature Protocol
F:5'-GTCTTCGACTTGGGACTGCTT-3'83 BP5 min - 95°C, 35 cycles: 1 min - 50°C (real-time) 15 sec -95°C
R:5'-GAGAAGACAAGATGGCTGAACTCT-3
5'-ROX-CATTCTGCCCTTCCTC-RTQ-1-3'
5'-FAM - ATTCTGCCATTCCTC-RTQ-1-3'

Genotyping is carried out using software IQ5 instrument manufactured by BioRad based on the data about the relative fluorescence for each probe. Mutant allele 460W α-adducin 1 causes a change in the primary structure of the protein, which may lead to the development of hypertensive reactions in pregnant women with gestosis.

To assess compliance of the observed distribution of genotypes expected based on equilibrium hardy-Weinberg used the criterion χ2observed heterozygosity, expected heterozygosity, the fixation index Wright. Association of alleles and genotypes DNA marker with a predisposition to develop hypertension is assessed through analysis of the contingency table is 2×2 with the calculation of the criterion χ2with the amendment of the Yates continuity and odds ratios (OR) with 95% confidence intervals (CI).

The invention is confirmed by the pictures shown on the drawings:

Figure 1 - chart Distribution of pregnant women having allele 460G locus

ADD1 G460W, the level of blood pressure;

Figure 2 - chart Distribution of pregnant women having genotype 460WW locus ADD1 G460W, the level of blood pressure".

As a concrete example of the analysis of the results of observations 241 pregnant. You the Orc pregnant was formed on the basis of the perinatal center regional hospital Belgorod. All women were divided into 3 groups, depending on the level of blood pressure: 1) >140/90 mm Hg - hypertensive patients (n=97); 2) <90/60 mm Hg - hypotension (n=7); 3) 90-140/60-90 mm Hg - normotonic (n=137).

As can be seen from the diagram presented in figure 1 and figure 2, the presence of the allele 460G (genotypes 460GG and 460GW) associated with normotone - in this group the highest percentage of pregnant women with normal blood pressure (58,1% against 14.3% in carriers of the genotype 460WW, OR=8,3 (Cl 1,02-189,43), p=0.05). On the contrary, the presence of 460W allele in the homozygous state causes the development of hypertension - the vast majority of pregnant with a mutant genotype have high blood pressure (85,7% vs. 38.9 percent in carriers of allele 460G, OR=0,1 (Cl 0,005-of 0.91), p=being 0.036).

Thus, the presence of genotype 460WW locus ADD1 G460W may be considered an adverse factor in the development of hypertension in pregnant and indicates the possible prognostic significance of this genetic marker.

Literature

1. Shechtman M.M., Burduli G.M. Diseases of organs of respiration and circulation in pregnancy. - M: "Triada-X, 2002. - 232 S.

2. Tkachev O., Baraboshkin AV Current issues of pathogenesis, diagnosis and pharmacotherapy of hypertension in pregnant women. - M: "PAGE", 2006 - 140 C.

3. Saveliev, M. Obstetrics. - M.: Medicine, 2000. - 160 S.

4. Torshin YOU, Gromov O.A. Vascular is e heart disease, brain and molecular genes. Castes: the role of molecular genes in vasoconstriction, vasodilation, metabolism of electrolytes and vascular remodeling // Difficult patient.- 2008. - V.6, №5-6. - P.8-11.

5. WSSE M. Psaty, Nicholas L. Smith, Susan R. Heckbert. et al. Diuretic Therapy, the alpha-Adducin Gene Variant, and the Risk ofMyocardial Infarction or Stroke in Persons With Treated Hypertension // JAMA. - 2002, April 3. - v.287, No. 13. - P.1680-1689.

6. Iwai, S., H. Akita, K. Kanazawa et al. Arg389Gly polymorphism of the human betal-adrenergic receptor in patients with nonfatal acute myocardial infarction // Am Heart J. - 2003. - v.1, No. 146. - R. 106-109.

7. Min-Ho Shin, Eun-Kyung Chung, Hee-Nam Kim et al. Alpha-adducin Gly460Trp and Essential Hypertension in Korea // J Korean Med Sci. - 2004. - No. 19. - P. 812-814.

8. Rubattu S., Stanzione R., Di Angelantonio, E., Zanda B., et al. The Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans // Stroke. - 2004. - v.4, No. 35. - P.814-818.

A method for predicting the development of hypertension in pregnancy, including DNA isolation from peripheral venous blood, conducting polymerase chain reaction identification data about the presence of the polymorphism of genes, characterized in that in case of carriage of genotype 460WW gene α-adducin 1 ADD1 G460W make a conclusion about the risk of developing high blood pressure in pregnant women.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method includes DNA separation from peripheral venous blood, analysis of genotype of locus - 322 VNTR of receptor of tumour necrosis factor of 2 type. In case if genotype 2/2-322 VNTR TNFR2 is determined -little area of myomatous knots is predicted. In case of genotypes 1/1-322 VNTR TNFR2 or 2/1-322 VNTR TNFR2, large area of myomatous knots is predicted.

EFFECT: invention application makes it possible to obtain criteria of estimating myomatous knots area, define tactics and individualize treatment basing on obtained data.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention describes method of predicting risk of development of therapeutic resistance in patients with bronchial asthma, by analysis of patients blood 3 month after beginning of treatment, DNA, separated from lymphocytes of peripheral venous patients blood, is analysed, values of levels of genes INC2, INC3, GJA8, SV2 expression are determined by microchips Affymetrix and probability of relating individuum to group with high risk of developing therapeutic resistance and low risk of therapeutic resistance development, and, R1 for individuums with high risk of therapeutic resistance development is estimated by formula: R1=-351.966-, 274*INC2+46.608*INC3+129.530*GLA8+105.438*SV2A, where 274; 46.608; 129.530; 105.438 - numeric values are coefficients; (-351.966) is constant for individuums with high risk of BA development; INC2, INC3, GJA8, SV2 are genotytpes, and R2 for individuums with low risk of therapeutic resistance development is calculated by formula: R2=-403.217-64.874*INC2+55.603*INC3+141.648*GJA8+116.342*SV2A, where 64.874; 55.603; 141.648; 116.342 are numeric values which are coefficients; (-403.217) is constant for individuums with high risk of BA and at R1>R2 high risk is predicted , and at R1<R2 low risk of therapeutic resistance is predicted in patient with bronchial asthma.

EFFECT: increase of accuracy and self-descriptiveness.

4 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: by ratio of integral estimations of spectrums of absorption of gas-secretions of smear from tonsils and breathed air in the range of wavelength 933-954 cm-1 conclusion about presence of disbacteriosis in oral cavity is made. Namely, if value of ratio of integral estimations of absorption of gas-secretion of smear from tonsils and breathed air is in interval 1.0±0.015 norm is diagnosed, in case of deviation from this values disbacteriosis is diagnosed.

EFFECT: simplification and reduction of time for diagnostics of oral cavity disbacteriosis.

2 ex, 4 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, management of postoperative regimen of patients after posterior stabilisation of lumbar spine. Before operation, on 3 and 7 day after operation enzymatic activity of lactadehydrogenase and creatininphosphokinase isoenzyme MM is analysed. Before operation and on 7 day after operation also analysed are electrophysiological parameters of paravertebral muscles by means of needle electromyography. Therapeutic rehabilitative activities are carried out depending on dynamics of enzymatic activity and electrophysiological indices of paravertebral muscles.

EFFECT: method makes it possible to reduce rehabilitation period.

4 cl

FIELD: medicine.

SUBSTANCE: sections are prepared by freezing a biopsy material plate in n-hexane cooled to temperature -95°C, and making sections in thickness no more than 7 mcm in a cryostat. The section is placed on a slide, drowned in an alcohol-aldehyde solution at room temperature (20-25°C) for 3 minutes, then washed in flowing water from a fixative for 30 seconds, stained with histological stains and enclosed by a cover glass consists under integumentary glass in the usual way. The preparations produced as described above preserve completely the structure of tissues and separate cells and allow describing lymphatic tumours according to the existing classifications. The method can be used in urgent histological examinations (intraoperative biopsies) as allows drawing up a conclusion decision for 20 minutes.

EFFECT: use of the method allows reducing working hours for the histological examinations required for diagnostics, in comparison with a conventional method, does not deteriorate the performed operations, and accelerates considerably drawing up the conclusion decisions.

3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: ventricular cerebral system is examined in fatal foetuses and fatal newborns of 22-27 weeks of gestation, namely immunohistochemistry of a germinal matrix within a postcornu is carried out by estimating an expression level of S-100 protein shown by stained neuroblast count. If observing 30 % or less of neuroblasts, ventriculomegaly is diagnosed, while stained 50% or more neuroblasts show hydrocephaly.

EFFECT: use of the declared technique enables cellular differentiation of ventriculomegaly and hydrocephaly in fatal foetuses and fatal newborns of 22-27 weeks of gestation.

4 ex

FIELD: medicine.

SUBSTANCE: patients' blood serum is analysed for a D-dimer level, a shunting value and a peak respiratory component amplitude. Their relative values are determined in relation to average values in healthy persons. The coefficient K is calculated by formula K=P1·P2·P3, where P1 is a value of a relative MHO level; P2 is a value of the relative D-dimer content; P3 is a relative value of a product of the shunting value and the peak respiratory component amplitude. If the coefficient exceeds 1.59±0.09, development of tromboembolic complications is predicted.

EFFECT: method extends the range of products for prediction of the tromboembolic complications in long bone fractures.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to detection of the presence, absence or number of specific DNA and RNA sequences. What is disclosed is a cartridge used to detect the presence, absence and/or number of a target nucleotide sequence in a sample containing one or more nucleic acid sequences; the cartridge comprises a common part containing a fluid processing means, a number of processing chambers which are used irrespective of application of the cartridge, and a water tank, and also waste compartments used for different fluids; also, the cartridge comprises one or more separate specific parts selected from a group containing a detector, a fluid container and an amplification devices, and the specific parts are coupled with the common part with using a bayonet joint. Also, there are disclosed a system and a method for detection of the presence, absence and/or quantity of the target nucleotide sequence in the sample containing one or more nucleic acid sequences.

EFFECT: more reliable detection.

14 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to neurology, infectious diseases, clinical immunology. It involves electric neuromyographic, clinical and clinical-biochemical examinations. If observing in the patient 6-9 of the 9 following signs: electric neuromyography showing signs of generalised primary axonal motor and sensory nerve disorder, age 46-60 years old, the presence of associated cardiovascular diseases, the absence of an indicated previous acute enteric infection, a level of haemoglobin less than 132 g/l, erythrocyte count 3.7*1012/l or less, alkaline phosphatase level more than 177 Un/l, CD 19+ lymphocytes count less than 0.19*109/l, IgA level more than 1.7 g/l, acute motor-sensor axonal neuropathy is diagnosed. If observing 4-9 of the 9 following signs: electric neuromyography showing signs of generalised, mainly motor, neural level of primary axonal disorder, age 60 years old and more, the presence of associated thyroid disease, the presence of a previous acute enteric infection one month ago and later, anti-GMI level 70 % and more, anti-GdIb level 90 % and more, a rheumatoid factor 5 IU/ml and more, IgE level less than 40 IU/ml, CD16+/CD56+ lymphocyte count 7 % and less, acute motor axonal neuropathy is diagnosed. If observing 2-4 of the 4 following signs: electric neuromyography showing signs of initially demyelinating process in peripheral nerves, IgM level more than 24 g/l, CD3+/HLA-DR+ lymphocyte count more than 2.0 %, IgE level more than 60 IU/ml, acute inflammatory demyelinating polyneuropathy is diagnosed. If observing 4-5 of the 5 following signs: anti-GM2 level 6 % and less, monocyte count more than 8.5 %, aspartate aminotransfrerase level 36 Un/l and less, IgA level 0.8 g/l less, detection of blood HSV type II IgM, chronic inflammatory demyelinating polyneuropathy with acute onset is diagnosed.

EFFECT: technique extends the range of products for differential diagnostics of forms of acute inflammatory polyneuropathy and chronic inflammatory demyelinating polyneuropathy with acute onset.

10 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: method of neutrophilic granulocyte recovery from peripheral blood consists in the fact that 2 ml of whole heparinised venous blood is mixed with sterile physiologic saline in proportions 2/3 and layered on a density bi-gradient of ficoll-verografin solutions with the volume of each gradient making 2 ml. It is followed with centrifugation for 40 minutes at 1500 rpm to observe a neutrophilic granulocyte ring of purity 98-100 % on a gradient border.

EFFECT: use of the method allows recovering a pure fraction of neutrophils from a smaller volume of peripheral blood, reducing a recovery time, and producing a greater percentage of viable cells as compared with existing methods of neutrophil recovery.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention represents primer sets for carrying out LIMP or PCR used for Saccharomyces pastorianus detection. Also, there are presented sets for Saccharomyces pastorianus detection containing a primer set according to the invention in a combination with a primer set for carrying out LAMP used for Saccharomyces bayanus detection, and also in a combination with a primer set for carrying out LAMP used for Saccharomyces cerevisiae and Saccharomyces pastorianus detection. There are presented methods for Saccharomyces pastorianus detection.

EFFECT: invention provides precise, quick and easy identification of Saccharomyces pastorianus yeast by means of PCR or LIMP.

19 cl, 4 dwg, 5 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: what is presented is a method for Apo2L/TRAIL sensitivity prediction of a malignant tissue or cell sampled from a mammal, involving the stages as follows: sampling a malignant tissue or cell from a mammal; analysing the sample malignant tissue or cell for detecting expression of one or more biomarkers selected from a group of fucosyl transferase 3, fucosyl transferase 6, sialyl-Lewis A and/or X antigen (antigens) where expression of one or more specified biomarkers is an indicator of the fact that the specified sampled tissue or cell is sensitive to apoptosis-inducing activity Apo2L/TRAIL. Also, what is described is a method of apoptosis induction in the sampled malignant tissue or cell of a mammal. What is offered is a method of treating a malignant tumour in a mammal. The inventions enables using the detection of expression of one or more biomarkers as the indicator of the fact that a sample is sensitive to apoptosis-inducing agents, such as Apo2L/TRAIL and DR5 agonist antibodies. Specific biomarkers to be examined include fucosyl transferases, particularly fucosyl transferase 3 (FUT3) and/or fucosyl transferase 6 (FUT6), as well as sialyl-Lewis A and/or X antigens.

EFFECT: method improvement.

35 cl, 22 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: cell suspension under investigation is incubated with biochip, containing immobilised on biochip antibodies, which have specificity to superficial antigens of investigated cells. After incubation, biochip is washed from non-specifically bound cells. Cells, which remain bound with biochip, are subjected to processing with labelled polynucleotide probes of one or several types with further hybridisation. Reading and processing of results are performed by presence of cell binding in area of biochip sites, containing immobilised antibodies, presence in them of determined superficial antigens is detected, and presence and character of binding of labelled polynucleotide probes are used to determine genetic signs in the same cells.

EFFECT: method application makes it possible to increase quantity of simultaneously determined superficial antigens on different cells with application of non-conjugated with label antibodies, simultaneously reducing number of used antibodies.

9 cl, 2 dwg, 2 ex

Biomarkers // 2429297

FIELD: medicine.

SUBSTANCE: what is offered is applying an analysis of p53(TP53) gene status and/or expression level as a biomarker while evaluating sensitivity of an individual suffering a proliferative disease to treatment by an mTOR inhibitor combined with a cytotoxic agent or while selecting individuals sensitive to the specified combined therapy for the following treatment of the disease by this method. Thus sensitivity to treatment of the proliferative disease by the mTOR inhibitor combined with the cytotoxic agent is predicted if wild-type functionally active p53 gene is found in a sample taken from the patient.

EFFECT: higher analysis accuracy.

14 cl, 5 ex

FIELD: medicine.

SUBSTANCE: what is offered is a method of structure stabilisation of thrombin binding DNA-aptamers, and also DNA-aptamers stabilised in such a way. The presented method provides formation of an additional base-stacking system by means of heterocycles or their analogues by means of increasing a surface of an aromatic system of heterocycles or their analogues, owing to using methods of determining a tertiary structure or molecular simulation with stating the fact of contact formation of the aromatic system of heterocyclic bases or their analogues with a G-quadruplex quartet which is related to a lateral loop.

EFFECT: method allows more effective assembly of antithrombin DNA-aptamers and improved structural stability under physiological conditions.

7 cl, 7 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves allele-specific Nested-PCR with primers which are matched with nucleotide sequences coding amino acids in positions 70-71 of the amino acid sequence. The allele-specific primers E70f1 - 5'-AGAAGGAGATCCTGGAGGATAG - 3' and R71r1 - 5'-CCTGTCCACCTCGGCCCGCCTATC - 3' are matched with a part of BoLA-DRB3 gene located on chromosome 23 (localisation 23q21). They interact only with the nucleotide sequences coding alleles *11, *23, *28 =*7A causing genetic stability to cattle leukaemia. Then sequencing primer Zond 70/71 5'-GCCCGGCTACACCTGT - 3' is used to identify homo- or heterozygosity of an individual by the given alleles. If observing the primers interacting with alleles *11, *23, *28 =*7A, animals are considered to be leukaemia stable, while the absence of interaction with the same alleles can enable to refer to leukaemia unstable, and to neutral.

EFFECT: invention can be used for mass genetic typing of BoLA-DRB3 leukaemia tolerable animals in livestock and commodity economies for animal selection in a nuclear stock.

2 dwg, 4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: set contains species-specific oligonucleotide primer pairs and appropriate fluorescent-marked probes for conducting one-stage instant identification of several human-pathogenic Orthopoxviruses (VARV, MPXV, CPXV and VACV) by means of real-time multiplex PCR.

EFFECT: invention is intended for instant diagnostics of human and animal Orthopoxvirus infections by real-time multiplex PCR.

10 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: tissue is homogenised in a buffer and centrifuged at 105000 g for 60-90 min at 0-4°C to produce a cytoplasmic fraction which is then incubated with 10 mM of phosphocreatine and 10 mcg/ml of phosphocreatine kinase for 25-45 minutes at 35°C. Cytoplasmic fraction proteins are divided by ammonium sulphate at three stages, at the first stage ammonium sulphate is added to 38% of saturation and centrifuged to isolate a precipitate containing a 26S-proteasome pool, at the second stage, a supernatant is added with ammonium sulphate to 42 % of saturation and centrifuged to isolate a precipitate containing ballast proteins, at the third stage to the supernatant is added with ammonium sulphate to 70 % of saturation and centrifuged to isolate a precipitate containing a 20S-npoteasome pool. Ammonium sulphate is added in portions during 20 min on a magnetic stirrer and further mixed for 20 minutes.

EFFECT: invention allows dividing native 26S- and 20S-proteasomes and isolating them in those amounts they exist in living cells, with preserving at most an undamaged 26S-proteasome structure.

3 cl, 1 ex

FIELD: medicine.

SUBSTANCE: there are offered versions of antibodies and their antigen-binding IL-13, particularly human IL-13 specific fragments. There are described: a pharmaceutical composition, a pharmaceutical compound of the antibody, versions of coding and hybridising nucleic acids and expression vectors. There are offered versions of: cells and methods of producing the antibody, methods of treating IL-13 associated disorders. A method of IL-13 detection in a sample is described.

EFFECT: use of the invention provides new IL-13 antibodies with KD about 10-10 M which can be used for diagnosing, preventing or treating one or more IL-13 associated diseases.

87 cl, 37 dwg, 5 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: method includes analysing aliquots of said sample by one or more methods of protein description specified in the chromatography. The method is based on genetic analysis techniques specified in RFLP and T-RFLP. These methods can be applied both separately, and in a combination. The offered methods allow obtaining the information on the presence and fractions of various individual proteins or coding sequences. The obtained information can be used for evaluating stability of a polyclonal cell line in process, and also estimating a structure of various parties of end polyclonal products.

EFFECT: methods allow describing the composition consisting more than of 10, 20 or greater number of antibodies.

16 cl, 18 dwg, 18 tbl, 14 ex

FIELD: medicine, psychiatry.

SUBSTANCE: one should isolate DNA out of lymphocytes of peripheral venous blood, then due to the method of polymerase chain reaction of DNA synthesis one should amplify the fragments of hSERT locus of serotonin carrier gene and at detecting genotype 12/10 one should predict the risk for the development of hallucino-delirious forms of psychoses of cerebro-atherosclerotic genesis.

EFFECT: more objective prediction of disease development.

3 ex

Up!